Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

This Phase I/IIa clinical study is testing an experimental treatment called GYA01 (CART84) for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) whose disease has come back after treatment (relapsed) or did not respond to treatment (refractory). GYA01 (CART84) is a type of CAR T-cell therapy. In this approach, a participant's own T cells (a type of immune cell) are collected and changed in a laboratory to help them better recognize and attack leukemia cells. The modified cells GYA01 (CART84) are then given back to the participant through an infusion into

Trial Details

NCT ID
NCT07471789
Phase
PHASE1 / PHASE2
Sponsor
Gyala Therapeutics
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CART84
Locations (sample)
  • Barcelona, Barcelona, Spain|41.38879,2.15899
  • Valencia, Valencia, Spain|39.47391,-0.37966

Key Eligibility Criteria

  • Age 18 years or older at the time of signing the informed consent.
  • Willing and able to give written, informed consent to the current study.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Diagnosed with AML or T-ALL with ≥5% blasts in BM and/or PB at screening, without any approved therapeutic alternative and one of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →